Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Carles X. Raventós"'
Publikováno v:
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
BMC Urology, Vol 20, Iss 1, Pp 1-11 (2020)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
BMC Urology
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
BMC Urology, Vol 20, Iss 1, Pp 1-11 (2020)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
BMC Urology
Background Genetic biomarkers are a promising and growing field in the management of bladder cancer in all stages. The aim of this paper is to understand the role of genetic urinary biomarkers in the follow up of patients with non muscle invasive bla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0196f22ee1daac24ede172cf9eb6444b
http://hdl.handle.net/2072/447778
http://hdl.handle.net/2072/447778
Autor:
Fernando Lozano, Marta Allué, Albert Carrion, Luis Castro, Jordi Ropero, Carles X. Raventós, Juan Morote, Raul Cocera
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Bladder cancer is one of the most expensive neoplasm. Recurrences rates achieves 50% of the patients at 5 years. After TUR BT is performed, many pacients experiment lowe...
Autor:
Gerardo Sanz, Carlos Hernandez, Marta Allué, Antonio Martínez, Joan Palou, Antonio Arruza, Juan Morote, Elisabet Ars, Diego Tejedor, Marta Artieda, Angel Borque, Roberto Llarena, Laureano Simon, Jokin del Amo, Miguel Herrera Suárez, Elena Carceller, Carles X. Raventós, Luis M. Esteban, Jacques Planas, Felipe Herranz
Publikováno v:
BJU International. 111:549-558
What's known on the subject? and What does the study add? Currently available nomograms to predict preoperative risk of early biochemical recurrence (EBCR) after radical prostatectomy are solely based on classic clinicopathological variables. Despite
Autor:
José Placer, Enrique Trilla, Juan Morote, Jacques Planas, Carles Salvador, Anna Orsola, Lluís Cecchini, Encabo G, Carles X. Raventós
Publikováno v:
BJU International. 104:1637-1640
OBJECTIVE To evaluate changes in bone mass and fracture risk in patients with prostate cancer on androgen-deprivation therapy (ADT) and with a basal T-score of >−2.0, who were treated with an oral bisphosphonate, as such patients treated with ADT a
Autor:
Juan Morote, Anna Orsola, Jacques Planas, Lluís Cecchini, Enrique Trilla, Carles X. Raventós, C. Salvador
Publikováno v:
BJU International. 99:812-816
To analyse the relationship between daily calcium intake (DCI) and bone mineral density (BMD) in patients with prostate cancer, and to assess if DCI is a risk factor for osteoporosis in this group of patients.DCI was assessed by a standard questionna
Autor:
Anna Orsola, Jaume Reventós, Carles Salvador, Enrique Trilla, Jacques Planas Morin, Juan Morote, Jose M. Abascal, Lluís Cecchini, Encabo G, Carles X. Raventós
Publikováno v:
Urology. 69:500-504
Objectives To know the prevalence of osteoporosis in patients with prostate cancer according to the duration of androgen deprivation therapy (ADT). Methods Dual energy x-ray absorptiometry was used to assess the bone mineral density (BMD) at the lumb
Autor:
Jose M. Abascal, Juan Morote, Luis Cecchini, Enrique Trilla, Carles X. Raventós, Jaume Reventós, S. Esquena, Roberto Catalán
Publikováno v:
Urologia Internationalis. 77:135-138
Objectives: It was the aim of this study to analyze the failure rates in achieving or maintaining castrate levels of serum testosterone in patients with advanced prostate cancer treated with the 3-month luteinizing hormone-releasing hormone agonist (
Autor:
Roberto Catalán, Carles X. Raventós, Enrique Trilla, Juan Morote, J M Abascal, J. Reventós, S Esquena, Lluís Cecchini, Jacques Planas, A Orsola
Publikováno v:
Scopus-Elsevier
The objective of this study was to analyze the value of the nadir level of prostate-specific antigen (PSA) to predict androgen-independent progression (AIP) in metastatic prostate cancer patients after androgen deprivation therapy. In a group of 185
Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer
Autor:
Anna Orsola, S. Esquena, Juan Morote, C. Salvador, Enrique Trilla, Jaume Reventós, Roberto Catalán, Jacques Planas, Carles X. Raventós, Luis Cecchini
Publikováno v:
Anti-Cancer Drugs. 16:863-866
We have assessed the effect of androgen deprivation therapy (ADT) in the thyroid function test in prostate cancer patients. Serum levels of tri-iodothyronine (T3), thyroxine (T4), free thyroxine (FT4) and thyroid-stimulating hormone (TSH) were determ
Publikováno v:
Urology. 65:49-54
Objectives To describe 3 cases of tumors located in the kidney that may relate collecting (Bellini) duct carcinoma (CDC) to urothelial cell carcinoma (UC). We hypothesized that these distinct tumor types may share a common origin. CDC is a subtype of